GGrantIndex
Sort

172,184 grants matching inflammation

Eradicating Latent SIV from the CNS by CCR5 Inhibition

$740,857
Joseph L Mankowski · Johns Hopkins University · R01 · FY2016 · NS

Eradicating Latent SIV from the CNS by CCR5 Inhibition

$740,857
Joseph L Mankowski · Johns Hopkins University · R01 · FY2017 · NS

Therapeutic vaccination to augment stringent response-specific T-cell immunity to MTB persisters

$740,856
Petros C Karakousis · Johns Hopkins University · R01 · FY2023 · AI

Tissue-Anchored vs. Circulating Engineered Enzyme Constructs for Immunometabolic Resolution of Psoriasis

$740,837
Benjamin George Keselowsky · University Of Florida · R01 · FY2025 · AI

Determinants of Midlife & Longitudinal Change in Cognitive Function: CARDIA Study

$740,757
Stephen Sidney · Kaiser Foundation Research Institute · R01 · FY2017 · HL

mTOR as a Central Regulator of iMCD Pathogenesis and Novel Therapeutic Target

$740,743
David C Fajgenbaum · University Of Pennsylvania · R01 · FY2019 · HL

Probing The Dark Matter of the Genome in the NHLBI Family Heart Study

$740,725
Michael A Province · Washington University · R01 · FY2015 · HL

SIV-induced Inflammation Causes Functional Impairment of the PNS

$740,714
Joseph L Mankowski · Johns Hopkins University · R01 · FY2017 · NS

SIV-induced Inflammation Causes Functional Impairment of the PNS

$740,714
Joseph L Mankowski · Johns Hopkins University · R01 · FY2019 · NS

SIV-induced Inflammation Causes Functional Impairment of the PNS

$740,714
Joseph L Mankowski · Johns Hopkins University · R01 · FY2018 · NS

ILC2s as drivers of lung dysfunction in response to early-life inflammation

$740,709
Anna E Beaudin · Utah State Higher Education System--University Of Utah · R01 · FY2025 · HL

Cardiac microstructure and the immune-inflammatory response to SARS-CoV-2

$740,687
Susan Cheng · Cedars-Sinai Medical Center · R01 · FY2025 · HL

Training Program in Environmental Toxicology

$740,637
F Peter Guengerich · Vanderbilt University · T32 · FY2022 · ES

DNA-based Immune Phenotyping in HNSCC for Biomarkers of Response to Immunotherapy

$740,622
Karl T Kelsey · Brown University · R01 · FY2021 · CA

INTEGRATIVE PHARMACOGENOMICS OF LEUKOTRIENE INHIBITION IN ASTHMA

$740,588
Kelan G Tantisira · Brigham And Women'S Hospital · R01 · FY2009 · HL

PAR2 Pepducins as a Novel Treatment of Idiopathic Pulmonary Fibrosis

$740,572
Athan Kuliopulos · Oasis Pharmaceuticals · R42 · FY2020 · HL

Impact of Clonal Hematopoiesis on the Progression of Kidney Disease

$740,540
Cassianne Robinson-Cohen · Vanderbilt University Medical Center · R01 · FY2022 · DK

Gut barrier function in Alzheimer’s disease

$740,468
Barbara Brigitta Bendlin · University Of Wisconsin-Madison · R01 · FY2024 · AG

Turbo Eye Drops to Treat Ocular Toxicity and Blindness from Sulfur Mustard

$740,416
Rajiv Ravindra Mohan · University Of Missouri-Columbia · U01 · FY2022 · EY

A microphysiological system of tendon inflammation and fibrosis for drug screening and efficacy testing

$740,400
Hani A Awad · University Of Rochester · UH3 · FY2022 · TR

Center for Childhood Asthma in the Urban Environment

$740,395
Johns Hopkins University · P01 · FY2004 · ES

New radiotracer development to study immune cell mobilization of granzyme proteolytic activity

$740,394
Michael John Evans · University Of California, San Francisco · R01 · FY2022 · AI

Transcriptome resources for comparative primate models of lentivirus infection

$740,376
Guido Silvestri · Emory University · R24 · FY2014 · OD

Inflammation in human obesity and type 2 diabetes

$740,375
Barbara Susanne Nikolajczyk · Boston University Medical Campus · R01 · FY2016 · DK

The role of Vpr-mediated cell cycle dysregulation in HIV-associated kidney disease

$740,348
Kyung W Lee · Icahn School Of Medicine At Mount Sinai · R01 · FY2023 · DK